Sat.Aug 03, 2024

article thumbnail

Healthful Diets Are Crucial, But Population-Level Follow-Through Remains a Challenge

Drug Topics

Health care professionals all agree that a healthy diet is the foundation of cardiovascular and cardiometabolic health, but follow-through on the population level is lacking.

209
209
article thumbnail

Expert: Psychosis in Alzheimer Disease Contributes to Rapid Cognitive, Functional Decline

Pharmacy Times

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaging patients’ relationships with caregivers, and increases isolation.

149
149
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Deeper Understanding of GLP-1 Mechanism of Action Will Open Doors for Future Uses

Drug Topics

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

131
131
article thumbnail

Opinion: Letters on Sonya Massey’s death, vaccine injuries, and much more

STAT

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.

Vaccines 105
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Small Doses: July 29 to August 2

Drug Topics

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

112
112
article thumbnail

Lenalidomide With Obinutuzumab Found Safe, Highly Active in Patients With Non-Hodgkin Lymphoma

Pharmacy Times

Investigators determine the efficacy and safety of the combination in a 2-phase trial.

139
139

More Trending

article thumbnail

How much does Vraylar cost with Medicare?

The Checkup by Singlecare

Vraylar is an atypical antipsychotic drug commonly prescribed for the treatment of schizophrenia and bipolar disorder, and it can also be used to treat other psychiatric disorders. It’s typically covered under commercial health insurance plans as well as Medicare and Medicaid. Medicare coverage of Vraylar falls under Medicare Part D prescription drug coverage, and understanding how much you’ll pay for Vraylar with Medicare can be a little confusing.

article thumbnail

Now Trending: PBM Breakdown, Exploring Specialty Drug Expenditures

Drug Topics

Check out this recap of articles published on our sister sites during the past week.

98
article thumbnail

Is Fasenra covered by Medicare?

The Checkup by Singlecare

The ability to breathe easily is something people may take for granted, but not people with severe eosinophilic asthma —when a certain type of white blood cells called eosinophils cause inflammation in the airways, impeding lung function. Often prescribed alongside systemic corticosteroids, Fasenra (benralizumab) is an injectable biologic medication that targets and eliminates those white blood cells.

article thumbnail

Igniting Pharma’s Potential?

BioPharm

Will Sanofi’s plan to recruit the younger generation through its participation in the upcoming 2024 Olympic and Paralympic Games, being held in Paris, pay off?

69
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Is Latuda covered by Medicare?

The Checkup by Singlecare

Latuda (lurasidone) is a brand-name prescription drug that’s approved by the Food and Drug Administration (FDA) to treat schizophrenia as well as bipolar depression associated with bipolar I disorder. It’s also sometimes prescribed off-label to treat major depressive disorder and other mental health conditions. The price of Latuda can vary based on several factors, including your location, pharmacy, and insurance coverage.